DK2906592T3 - Proteolytic inactivation of selected proteins in bacterial extracts for enhanced expression - Google Patents

Proteolytic inactivation of selected proteins in bacterial extracts for enhanced expression Download PDF

Info

Publication number
DK2906592T3
DK2906592T3 DK13779699.1T DK13779699T DK2906592T3 DK 2906592 T3 DK2906592 T3 DK 2906592T3 DK 13779699 T DK13779699 T DK 13779699T DK 2906592 T3 DK2906592 T3 DK 2906592T3
Authority
DK
Denmark
Prior art keywords
protein
seq
cell
arg
amino acid
Prior art date
Application number
DK13779699.1T
Other languages
Danish (da)
English (en)
Inventor
Christopher J Murray
Junhao Yang
Heather Stephenson
Christopher D Thanos
Original Assignee
Sutro Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sutro Biopharma Inc filed Critical Sutro Biopharma Inc
Application granted granted Critical
Publication of DK2906592T3 publication Critical patent/DK2906592T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/686Polymerase chain reaction [PCR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/04Preparation or injection of sample to be analysed
    • G01N30/06Preparation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
DK13779699.1T 2012-10-12 2013-10-08 Proteolytic inactivation of selected proteins in bacterial extracts for enhanced expression DK2906592T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713245P 2012-10-12 2012-10-12
PCT/US2013/063804 WO2014058830A1 (en) 2012-10-12 2013-10-08 Proteolytic inactivation of select proteins in bacterial extracts for improved expression

Publications (1)

Publication Number Publication Date
DK2906592T3 true DK2906592T3 (en) 2018-12-10

Family

ID=49447839

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13779699.1T DK2906592T3 (en) 2012-10-12 2013-10-08 Proteolytic inactivation of selected proteins in bacterial extracts for enhanced expression

Country Status (14)

Country Link
US (3) US9650621B2 (enExample)
EP (1) EP2906592B1 (enExample)
JP (3) JP6421122B2 (enExample)
KR (1) KR102018863B1 (enExample)
CN (1) CN104837863B (enExample)
AU (1) AU2013329464C1 (enExample)
CA (1) CA2887355C (enExample)
DK (1) DK2906592T3 (enExample)
ES (1) ES2694683T3 (enExample)
HU (1) HUE041721T2 (enExample)
IL (1) IL238095B (enExample)
PL (1) PL2906592T3 (enExample)
SG (1) SG11201502875VA (enExample)
WO (1) WO2014058830A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6421122B2 (ja) * 2012-10-12 2018-11-07 ストロ バイオファーマ, インコーポレイテッド 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化
SG10202108497TA (en) * 2013-04-19 2021-09-29 Sutro Biopharma Inc Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones
US10316322B2 (en) * 2014-07-02 2019-06-11 Sutro Biopharma, Inc. High growth capacity auxotrophic Escherichia coli and methods of use
CN108779446B (zh) * 2016-01-13 2023-04-21 新英格兰生物实验室公司 T7 rna聚合酶的热稳定变体
DK3562503T3 (da) 2016-12-30 2025-05-26 Vaxcyte Inc Polypeptid-antigen-konjugater med ikke-naturlige aminosyrer
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN106801047A (zh) * 2016-12-30 2017-06-06 武汉金开瑞生物工程有限公司 一种通过无细胞蛋白合成系统制备半胱氨酸蛋白酶的方法
TW202426655A (zh) 2017-07-11 2024-07-01 美商新索思股份有限公司 非天然核苷酸之導入及其方法
MA49767A (fr) 2017-08-03 2021-05-26 Synthorx Inc Conjugués de cytokine pour le traitement de maladies auto-immunes
SG11202003147XA (en) 2017-10-12 2020-05-28 Vaxcyte Inc Periodontitis vaccine and related compositions and method of use
CN112004547A (zh) 2018-02-26 2020-11-27 新索思股份有限公司 Il-15缀合物及其用途
EP3820992A2 (en) 2018-07-11 2021-05-19 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CN108949796A (zh) * 2018-07-27 2018-12-07 张家港市华天药业有限公司 一种用于合成谷胱甘肽的重组菌及谷胱甘肽的合成方法
CN109055291A (zh) * 2018-07-31 2018-12-21 张家港市华天药业有限公司 用于合成谷胱甘肽的重组菌及谷胱甘肽的合成方法
CN113260374A (zh) 2018-11-08 2021-08-13 新索思股份有限公司 白介素10缀合物及其用途
CA3127689A1 (en) 2019-02-06 2020-08-13 Synthorx, Inc. Il-2 conjugates and methods of use thereof
CN114025789A (zh) 2019-04-02 2022-02-08 Vaxcyte公司 侵入质粒抗原b的经优化的无细胞合成和有关的组合物及使用方法
WO2021030706A1 (en) 2019-08-15 2021-02-18 Synthorx, Inc. Immuno oncology combination therapies with il-2 conjugates
AU2020347154A1 (en) 2019-09-10 2022-03-03 Synthorx, Inc. IL-2 conjugates and methods of use to treat autoimmune diseases
EP4054644A1 (en) 2019-11-04 2022-09-14 Synthorx, Inc. Interleukin 10 conjugates and uses thereof
US12351850B2 (en) * 2020-04-30 2025-07-08 Sutro Biopharma, Inc. Methods of producing full-length antibodies using E. coli
KR20230027235A (ko) 2020-06-25 2023-02-27 신톡스, 인크. Il-2 콘쥬게이트 및 항-egfr 항체를 사용한 면역 종양학 병용 요법
TWI899326B (zh) * 2020-09-14 2025-10-01 美商蘇特羅生物製藥公司 使用無細胞蛋白質合成系統來大規模生產抗體之方法
CA3194880A1 (en) 2020-10-09 2022-04-14 Carolina E. CAFFARO Immuno oncology therapies with il-2 conjugates
MX2023004029A (es) 2020-10-09 2023-04-27 Synthorx Inc Terapia de combinacion de inmunoncologia con conjugados de il-2 y pembrolizumab.
WO2022174102A1 (en) 2021-02-12 2022-08-18 Synthorx, Inc. Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
WO2022174101A1 (en) 2021-02-12 2022-08-18 Synthorx, Inc. Skin cancer combination therapy with il-2 conjugates and cemiplimab
CN113322267B (zh) * 2021-03-15 2024-01-05 天津大学 系统在提高非天然氨基酸的插入效率中的应用
TW202313679A (zh) 2021-06-03 2023-04-01 美商欣爍克斯公司 包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
EP4452327A1 (en) 2021-12-20 2024-10-30 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023122750A1 (en) 2021-12-23 2023-06-29 Synthorx, Inc. Cancer combination therapy with il-2 conjugates and cetuximab
WO2024136899A1 (en) 2022-12-21 2024-06-27 Synthorx, Inc. Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
WO2024196937A1 (en) 2023-03-20 2024-09-26 Synthorx, Inc. Cancer therapy with il-2 peg conjugates
WO2025015041A1 (en) * 2023-07-12 2025-01-16 University Of Washington Rna-only, positive control target for clinical diagnostic testing
WO2025158385A1 (en) 2024-01-25 2025-07-31 Genzyme Corporation Pegylated il-2 for suppressing adaptive immune response to gene therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100916169B1 (ko) * 1999-03-04 2009-09-08 아스비오파마 가부시키가이샤 OmpT 프로테아제에 의한 절단 제어 방법
EP1356036B1 (en) 2001-01-25 2008-05-07 Anthony C. Forster Process and compositions for peptide, protein and peptidomimetic synthesis
AU2003259912B2 (en) 2002-08-19 2008-10-23 The Board Of Trustees Of The Leland Stanford Junior University Improved methods of in vitro protein synthesis
DE10336705A1 (de) * 2003-08-06 2005-03-10 Rina Netzwerk Rna Technologien Verfahren zur Herstellung eines Lysats zur zellfreien Proteinbiosynthese
KR101099398B1 (ko) * 2003-09-30 2011-12-27 아스비오파마 가부시키가이샤 OmpT 프로테아제 변이체를 이용한 폴리펩티드의 절단 방법
DE602006014362D1 (de) * 2005-02-02 2010-07-01 Univ Bayreuth Esterasen zur überwachung der proteinbiosynthese in vitro
US8367588B2 (en) * 2005-10-12 2013-02-05 The Scripps Research Institute Selective posttranslational modification of phage-displayed polypeptides
BRPI0709603A2 (pt) * 2006-03-16 2011-07-19 Scripps Research Inst expressão de proteìnas geneticamente programada contendo o aminoácido não natural fenilselenocisteìna
JP5798489B2 (ja) 2009-01-12 2015-10-21 ストロ バイオファーマ, インコーポレイテッド インビトロタンパク質合成システムを用いて非天然アミノ酸をタンパク質に選択的に導入するためのモノチャージシステム
JP6421122B2 (ja) 2012-10-12 2018-11-07 ストロ バイオファーマ, インコーポレイテッド 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化

Also Published As

Publication number Publication date
AU2013329464A1 (en) 2015-05-14
ES2694683T3 (es) 2018-12-26
JP6421122B2 (ja) 2018-11-07
AU2013329464C1 (en) 2018-02-15
JP2021003134A (ja) 2021-01-14
US10450353B2 (en) 2019-10-22
EP2906592A1 (en) 2015-08-19
KR20150064209A (ko) 2015-06-10
KR102018863B1 (ko) 2019-09-05
CN104837863A (zh) 2015-08-12
US20150259664A1 (en) 2015-09-17
US20170283469A1 (en) 2017-10-05
SG11201502875VA (en) 2015-06-29
US20200062807A1 (en) 2020-02-27
US11261219B2 (en) 2022-03-01
CA2887355C (en) 2023-03-07
CN104837863B (zh) 2018-06-19
HUE041721T2 (hu) 2019-05-28
JP2015531407A (ja) 2015-11-02
CA2887355A1 (en) 2014-04-17
IL238095B (en) 2019-11-28
US9650621B2 (en) 2017-05-16
PL2906592T3 (pl) 2019-07-31
WO2014058830A1 (en) 2014-04-17
IL238095A0 (en) 2015-05-31
JP2018029621A (ja) 2018-03-01
EP2906592B1 (en) 2018-10-03
AU2013329464B2 (en) 2017-07-27

Similar Documents

Publication Publication Date Title
US11261219B2 (en) Proteolytic inactivation of select proteins in bacterial extracts for improved expression
KR102289258B1 (ko) 상승된 수준의 외인성 샤페론을 갖는 세포 추출물을 이용한 박테리아 세포 비함유 합성 시스템에서의 생물학적 활성 단백질의 발현
CN102348807B (zh) 利用体外蛋白合成体系将非天然氨基酸引入蛋白的单装载体系
CN107614689A (zh) 用于将非天然氨基酸并入蛋白质中的平台
WO2014194129A2 (en) Cell-free synthetic incorporation of non-natural amino acids into proteins
KR20170074120A (ko) 과당으로부터 알로오스를 생산하는 균주 및 이를 이용한 알로오스 생산방법
Mohanty et al. Bioprocess optimization for the overproduction of catalytic domain of ubiquitin-like protease 1 (Ulp1) from S. cerevisiae in E. coli fed-batch culture
JP4936290B2 (ja) 非天然型アミノ酸を組み込んだタンパク質の製造方法
WO2026008852A2 (en) Optimized media for highly efficient cell-free protein expression systems
JP6472085B2 (ja) 組み換えタンパク質、組み換え遺伝子、組み換えベクター、形質転換体、ピルビン酸含有複合型糖鎖の製造方法、ピルビン酸含有複合型糖鎖修飾タンパク質の製造方法、ピルビン酸含有複合型糖鎖およびピルビン酸含有複合型糖鎖修飾タンパク質
WO2026008850A1 (en) Linear nucleic acid templates for high-efficient cell-free protein expression
Novikov et al. The highly efficient expression of the aspartase gene (L-aspartate ammonia-lyase) in Escherichia coli cells
HK1167003A (en) Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system
KR20160025661A (ko) 디제너러시 리프로그래밍을 통한 비천연 단백질 합성 방법